Stoke Therapeutics, Inc. has announced the issuance of stock options to two new employees as part of its compensation package under Nasdaq Listing Rule 5635(c)(4). Effective June 16, 2025, these options allow for the purchase of a total of 37,200 shares at an exercise price of $11.70 per share, matching the closing price of the company's common stock on the same date. The options will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date and the remainder vesting monthly over the subsequent 36 months, contingent upon the employees' continued service. The options have a 10-year term and are governed by the 2023 Inducement Plan and related stock option agreements.